<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40864">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574403</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0061</org_study_id>
    <nct_id>NCT02574403</nct_id>
  </id_info>
  <brief_title>Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS</brief_title>
  <acronym>STOPECU</acronym>
  <official_title>Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atypical hemolytic syndrome (aHUS) is a severe renal disease affecting children and adults.
      It is characterized by the occlusion of intrarenal vessels due to the presence of
      platelet/fibrin thrombi, and leads to end-stage renal disease in up to 2/3 of patients. The
      discovery of complement alternative pathway as a major risk factor for aHUS has led to the
      design of a disease-specific treatment, the anti-C5 monoclonal antibody, eculizumab.
      Complement inhibition using eculizumab has clearly improved the renal outcome of aHUS
      patients with a dramatic decrease in the risk of end-stage renal disease. However, the
      optimal duration of eculizumab therapy is still debated. The present study aims to assess
      the feasibility and safety of the discontinuation of eculizumab treatment in children and
      adults with aHUS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A visit (physical examination; blood pressure measurement) will be performed every month for
      3 months, and every 3 months for 21 months.

      Blood (serum creatinine, platelet count, hemoglobin, LDH, haptoglobin) and urine
      (proteinuria/creatininuria ratio and microscopic hematuria) tests will be performed every 2
      weeks from inclusion to M6 and subsequently every month starting M7 Urine dipstick (for
      albuminuria and microscopic hematuria) will be performed by the patients at home at least
      twice a week.

      Markers of complement activation and biomarkers of endothelial cells activation and immune
      cells activation will be assessed at baseline, M1, M3, M6, M9, M12, M18 and M24.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of aHUS relapse during 2 years of follow-up after eculizumab discontinuation</measure>
    <time_frame>24 months</time_frame>
    <description>aHUS relapse will be defined by the coexistence of at least two of the following:
thrombocytopenia (platelet count &lt; 150 G/L),
mechanical hemolytical anaemia (Hb &lt; 10 g/dl, LDH &gt; upper limit of normal, undetectable haptoglobin, presence of schizocytes on blood smear),
acute kidney injury (serum creatinine and/or proteinuria/creatininuria &gt; upper limit of normal for age or an increase &gt; 15% compared to baseline levels ),
features of thrombotic microangiopathy (glomerular and/or arteriolar thrombi, doubles contours, endothelial cells detachment) in a kidney biopsy, if performed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atypical Hemolytic Uremic Syndrome</condition>
  <arm_group>
    <arm_group_label>without eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eculizumab</intervention_name>
    <description>eculizumab discontinuation</description>
    <arm_group_label>without eculizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children and adults under eculizumab treatment for aHUS (initial episode or relapse)
             defined by at least two of the following: thrombocytopenia (platelet count &lt; 150
             G/L), mechanical hemolytical anaemia (Hb &lt; 10 g:dl, LDH &gt; upper limit of normal,
             undetectable haptoglobin, presence of schizocytes on blood smear), acute kidney
             injury (serum creatinine and/or proteinuria/creatininuria &gt; upper limit of normal for
             age or an increase &gt; 15% compared to baseline levels )

          2. Patients not requiring dialysis.

          3. Adults: HUS remission and normal or stabilized renal function under eculizumab
             treatment since at least 6 months (3 months in patients with MCP mutations)

          4. Children: age &gt; 3 years at eculizumab withdrawal; HUS remission and normal renal
             function under eculizumab treatment since at least 3 months in children with isolated
             MCP mutation, at least 6 months in children with complement mutation other than MCP.

        Exclusion Criteria:

          1. Patients on dialysis.

          2. Women treated with eculizumab starting or planning a pregnancy. Pregnancy including
             the post-partum period is high-risk periods for the occurrence of aHUS.

          3. Patients who did not give informed consent.

          4. Patients under protection of a judicial authority

        Patients can be enrolled in the study within ten weeks after Eculizumab stop.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fadi FAKHOURI, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Nantes CHU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fadi FAKHOURI, Pr</last_name>
    <email>fadi.fakhouri@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérard CHAMPION</last_name>
    </contact>
    <investigator>
      <last_name>Gérard CHAMPION</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besancon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François NOBILI</last_name>
    </contact>
    <investigator>
      <last_name>François NOBILI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yahsou DELMAS</last_name>
    </contact>
    <investigator>
      <last_name>Yahsou DELMAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte LLANAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie CHATELET</last_name>
    </contact>
    <investigator>
      <last_name>Valérie CHATELET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe ECKART</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH métropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphane BALLY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane MOUSSON</last_name>
    </contact>
    <investigator>
      <last_name>Christiane MOUSSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Philippe COINDRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François PROVOT</last_name>
    </contact>
    <investigator>
      <last_name>Francois PROVOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annie LAHOCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire POUTEIL NOBLE</last_name>
    </contact>
    <investigator>
      <last_name>Claire POUTEIL NOBLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Laure SELLIER-LECLERC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde CAILLIEZ</last_name>
    </contact>
    <contact_backup>
      <last_name>Stéphane BURTEY</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mathilde CAILLIEZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane BURTEY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Metz Thionville</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe MIRGAINE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moglie LE QUINTREC DONNETTE</last_name>
    </contact>
    <contact_backup>
      <last_name>Marc FILA</last_name>
    </contact_backup>
    <investigator>
      <last_name>Moglie LE QUINTREC DONNETTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc FILA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fadi FAKHOURI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>NIce</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent ESNAULT</last_name>
    </contact>
    <contact_backup>
      <last_name>Etienne BERARD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Vincent ESNAULT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne BERARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BICHAT</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Quentin RAIMBOURG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine DURRBACH</last_name>
    </contact>
    <investigator>
      <last_name>Antoine DURRBACH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges DESCHENES</last_name>
    </contact>
    <investigator>
      <last_name>Georges DESCHENES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude SERVAIS</last_name>
    </contact>
    <investigator>
      <last_name>Aude SERVAIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémi SALOMON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric RONDEAU</last_name>
    </contact>
    <investigator>
      <last_name>Eric RONDEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis GLOTZ</last_name>
    </contact>
    <investigator>
      <last_name>Denis GLOTZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain WYNCKEL</last_name>
    </contact>
    <investigator>
      <last_name>Alain WYNCKEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie TAQUE</last_name>
    </contact>
    <investigator>
      <last_name>Sophie TAQUE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LEGALLICIER</last_name>
    </contact>
    <contact_backup>
      <last_name>Francoise BROUX</last_name>
    </contact_backup>
    <investigator>
      <last_name>Bruno LEGALLICIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francoise BROUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU saint etienne</name>
      <address>
        <city>Saint Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Alpes Léman</name>
      <address>
        <city>Sallanches</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William HANF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno MOULIN</last_name>
    </contact>
    <contact_backup>
      <last_name>Michel FISCHBACH</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michel FISCHBACH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno MOULIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital FOCH</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Tricot</last_name>
    </contact>
    <investigator>
      <last_name>Leila Tricot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David RIBES</last_name>
    </contact>
    <contact_backup>
      <last_name>Arnaud GARNIER</last_name>
    </contact_backup>
    <investigator>
      <last_name>David RIBES</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud GARNIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie CLOAREC</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie CLOAREC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 20, 2016</lastchanged_date>
  <firstreceived_date>October 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atypical hemolytic uremic syndrome (aHUS)</keyword>
  <keyword>eculizumab discontinuation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
